Skip to content

Thalamic Nuclei Volumes in Multiple Sclerosis

Differential Vulnerability of Individual Thalamic Nuclei: Toward New Biomarkers in Multiple Sclerosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05002764
Acronym
THALNUC-MS
Enrollment
2000
Registered
2021-08-12
Start date
2021-07-01
Completion date
2023-07-01
Last updated
2021-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple sclerosis, Thalamus, Nuclei, Atrophy

Brief summary

The thalamus is composed of several nuclei interlocked in a complex anatomy. In multiple sclerosis (MS), the thalamus can be altered due to disconnection by white matter lesions and due to direct damages that could be partly mediated by CSF. Due to such pathophysiology and complex anatomy, some nuclei could be more vulnerable to multiple sclerosis than others. We will test this hypothesis by using a new algorithm to automatically segment several nuclei that we will be applied to the French national MS database

Interventions

None listed

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

: * Patient older than 18 years old. * With Multiple Sclerosis according to Mc Donald 2017 criteria or with clinically isolated syndrome and included with OFSEP cohort. * Phenotype known (RR, SP, PP or CIS). * Date of diagnosis known. * With at least one MRI that includes 3D T1 and FLAIR at 1.5T or 3T.

Exclusion criteria

: * Stroke * Other causes of dementia not caused by Multiple Sclerosis (Alzheimer's disease, Parkinsonian syndromes…)

Design outcomes

Primary

MeasureTime frameDescription
Volume of thalamic nucleiAt inclusion in the cohortVolume of individual thalamic nuclei according to disease duration.

Countries

France

Contacts

Primary ContactThomas Tourdias, Pr
thomas.tourdias@chu-bordeaux.fr05 56 79 56 04

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026